title: Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men.
abstract: OBJECTIVE
  This study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in overweight and obese (BMI > or = 26 kg/m(2)) men.
  
  
  METHODS
  Thirty subjects (forskolin, n = 15; placebo, n = 15) were studied in a randomized, double-blind, placebo-controlled study for 12 weeks.
  
  
  RESULTS
  Forskolin was shown to elicit favorable changes in body composition by significantly decreasing body fat percentage (BF%) and fat mass (FM) as determined by DXA compared with the placebo group (p < or = 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week trial compared with the placebo group (p < or = 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p < or = 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 +/- 33.77% in the forskolin group compared with a decrease of 1.08 +/- 18.35% in the placebo group.
  
  
  CONCLUSIONS
  Oral ingestion of forskolin (250 mg of 10% forskolin extract twice a day) for a 12-week period was shown to favorably alter body composition while concurrently increasing bone mass and serum free testosterone levels in overweight and obese men. The results indicate that forskolin is a possible therapeutic agent for the management and treatment of obesity.
authors.affiliation: University of Kansas, Department of Health, Sport and Exercise Sciences, Applied Physiology Laboratory, Lawrence, KS 66045, USA. mgodard@ku.edu
authors.forename: Michael P
authors.initials: MP
authors.lastname: Godard
authors.forename: Brad A
authors.initials: BA
authors.lastname: Johnson
authors.forename: Scott R
authors.initials: SR
authors.lastname: Richmond
mesh_terms: D000328:Adult; D001481:Basal Metabolism; D001794:Blood Pressure / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D005576:Colforsin / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D050177:Overweight / Q000187:drug effects* / Q000502:physiology; D013739:Testosterone / Q000097:blood*
chemical_list: D005576:Colforsin; D013739:Testosterone